| Literature DB >> 33545081 |
Tae Wan Kim1, Jinghua Piao2, So Yeon Koo3, Sonja Kriks4, Sun Young Chung1, Doron Betel5, Nicholas D Socci6, Se Joon Choi7, Susan Zabierowski8, Brittany N Dubose8, Ellen J Hill8, Eugene V Mosharov7, Stefan Irion1, Mark J Tomishima8, Viviane Tabar9, Lorenz Studer10.
Abstract
Human pluripotent stem cells show considerable promise for applications in regenerative medicine, including the development of cell replacement paradigms for the treatment of Parkinson's disease. Protocols have been developed to generate authentic midbrain dopamine (mDA) neurons capable of reversing dopamine-related deficits in animal models of Parkinson's disease. However, the generation of mDA neurons at clinical scale suitable for human application remains an important challenge. Here, we present an mDA neuron derivation protocol based on a two-step WNT signaling activation strategy that improves expression of midbrain markers, such as Engrailed-1 (EN1), while minimizing expression of contaminating posterior (hindbrain) and anterior (diencephalic) lineage markers. The resulting neurons exhibit molecular, biochemical, and electrophysiological properties of mDA neurons. Cryopreserved mDA neuron precursors can be successfully transplanted into 6-hydroxydopamine (6OHDA) lesioned rats to induce recovery of amphetamine-induced rotation behavior. The protocol presented here is the basis for clinical-grade mDA neuron production and preclinical safety and efficacy studies.Entities:
Keywords: Parkinson’s disease; WNT signaling; cell therapy; directed differentiation; human embryonic stem cells; human-induced pluripotent stem cells; midbrain development; neural patterning; preclinical study; transplantation
Mesh:
Year: 2021 PMID: 33545081 PMCID: PMC8006469 DOI: 10.1016/j.stem.2021.01.005
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633